IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC reduced its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 15.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 29,553 shares of the company’s stock after selling 5,542 shares during the period. Orion Portfolio Solutions LLC’s holdings in IDEAYA Biosciences were worth $936,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Allworth Financial LP grew its stake in shares of IDEAYA Biosciences by 800.0% in the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 800 shares during the last quarter. Covestor Ltd boosted its holdings in IDEAYA Biosciences by 23,050.0% during the third quarter. Covestor Ltd now owns 926 shares of the company’s stock worth $29,000 after buying an additional 922 shares in the last quarter. Quest Partners LLC acquired a new position in IDEAYA Biosciences in the second quarter worth approximately $41,000. US Bancorp DE increased its holdings in shares of IDEAYA Biosciences by 67.2% in the third quarter. US Bancorp DE now owns 1,714 shares of the company’s stock valued at $54,000 after buying an additional 689 shares in the last quarter. Finally, Comerica Bank lifted its position in shares of IDEAYA Biosciences by 723.5% during the 1st quarter. Comerica Bank now owns 1,507 shares of the company’s stock valued at $66,000 after acquiring an additional 1,324 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Oppenheimer reaffirmed an “outperform” rating and set a $53.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. Wedbush restated an “outperform” rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a report on Monday, November 4th. UBS Group initiated coverage on shares of IDEAYA Biosciences in a report on Thursday, October 24th. They issued a “buy” rating and a $50.00 target price for the company. Citigroup cut their price target on shares of IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating on the stock in a report on Tuesday, August 27th. Finally, Leerink Partnrs lowered shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 5th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, IDEAYA Biosciences has an average rating of “Moderate Buy” and a consensus target price of $53.67.

IDEAYA Biosciences Stock Down 2.3 %

Shares of NASDAQ:IDYA opened at $25.19 on Monday. The firm has a fifty day moving average of $28.73 and a two-hundred day moving average of $34.37. IDEAYA Biosciences, Inc. has a 12-month low of $24.72 and a 12-month high of $47.74. The firm has a market capitalization of $2.18 billion, a P/E ratio of -10.81 and a beta of 0.79.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.03. During the same period last year, the firm posted ($0.46) EPS. Equities research analysts expect that IDEAYA Biosciences, Inc. will post -2.45 earnings per share for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.